Press Releases

For press releases issued prior to June 2, 2014, the date of the spin-off of Theravance Biopharma, Inc. from Theravance, Inc., please visit Innoviva, Inc.

Date Title  
11/01/16

Retrospective Analyses of VIBATIV (telavancin) in Osteomyelitis Patients and in vitro Potency in Challenging Pathogens

10/31/16

TOUR Results Highlight Clinical Response Rates for VIBATIV® (telavancin) in a Range of Difficult-to-Treat Infections; Real-World Use of Antibiotic Observed in Approved Indications, as well as Bone and Joint Infections and Bacteremia

10/28/16
DUBLIN , Oct. 27, 2016 /PRNewswire/ -- Theravance Biopharma, Inc. ( NASDAQ : TBPH) (" Theravance Biopharma " or the "Company") today announced the pricing of concurrent underwritten public offerings of 3,850,000 ordinary shares (the "Shares") at a price to the public of $26.00 per share and $200
10/26/16
DUBLIN , Oct. 26, 2016 /PRNewswire/ -- Theravance Biopharma, Inc. ( NASDAQ : TBPH) (" Theravance Biopharma " or the "Company") today announced that it intends to commence concurrent underwritten public offerings, subject to market and other conditions, of $100 million of its ordinary shares (the
10/25/16

Study Findings Consistent with Single-Ascending Dose (SAD) Data, Demonstrating Sustained Target Engagement, Low Levels of Renal Elimination, Favorable Safety and Tolerability Profile

10/20/16
Revefenacin Meets Primary Efficacy Endpoint and is Shown to be Well-Tolerated in Both Studies; Twelve-Month Safety Trial Ongoing and Targeted for Completion in 2017
10/18/16

First Presentation of TOUR Data Highlights Real World Experience with VIBATIV in Range of Difficult-to-Treat Infections; Additional VIBATIV Presentations Report Results from Retrospective Analysis in Osteomyelitis Patients and Multiple Studies Evaluating in vitro Potency in Challenging Pathogens Compared to Other Commercialized Antibiotics

10/06/16
DUBLIN, IRELAND -- (Marketwired) -- 10/06/16 -- Theravance Biopharma, Inc. ( NASDAQ : TBPH) ("Theravance Biopharma" or the "Company") announced today that stock options to purchase an aggregate of 13,350 of the Company's ordinary shares were granted to five new non-executive officer employees on
10/04/16

Intestinally Restricted Pan-Janus Kinase (JAK) Inhibitor Designed to Act Directly at Site of Inflammation in the Intestinal Wall With Minimal Systemic Exposure

09/07/16
DUBLIN, IRELAND -- (Marketwired) -- 09/07/16 -- Theravance Biopharma, Inc. ( NASDAQ : TBPH) Statistically Significant Benefits in Lung Function, Health-Related Quality of Life and Annual Rate of Exacerbations Observed for Closed Triple as Compared to Symbicort ® Turbohaler ® Theravance